BioTuesdays

Category - Markets

Alector

BTIG starts Alector at buy; PT $28

BTIG initiated coverage of Alector (NASDAQ:ALEC) with a “buy” rating and $28 price target. The stock closed at $15.80 on Nov. 20. Alector is focused on the immune system of the brain as a major player in...

Calithera Biosciences

HCW starts Calithera Biosciences at buy; PT $7

H.C. Wainwright launched coverage of Calithera Biosciences (NASDAQ:CALA) with a “buy” rating and $7 price target. The stock closed at $3.38 on Nov. 18. Calithera is developing therapies that target cellular metabolic...

SELLAS Life Sciences Logo

Maxim ups SELLAS to buy; sets PT $12

Maxim Group upgraded SELLAS Life Sciences (NASDAQ:SLS) to “buy” from “hold” with a price target of $12 after the company removed a financing overhang. The stock closed at $6.17 on Nov. 14. SELLAS ended the latest...

ResTORbio

SVB Leerink cuts ResTORbio to MP; PT to $2 from $40

SVB Leerink downgraded ResTORbio (NASDAQ:TORC) to “market perform” from “outperform” and slashed its price to $2 from $40 after a failure of first of the company’s two ongoing Phase 3 trials in respiratory infection...

Leap Therapeutics

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

H.C. Wainwright lowered its price target for Leap Therapeutics (NASDAQ:LPTX) to $3.25 from $7.50 after the company decided to re-allocate resources and focus on advancing DKN-01, its anti-Dickkopf-1 antibody, while...

Genocea Biosciences

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

Liminal BioSciences

Liminal BioSciences to begin trading on NASDAQ

Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto...

Motus GI Holdings

AGP cuts PT for Motus GI to $3.75 from $6

Alliance Global Partners lowered its price target for Motus GI Holdings (NASDAQ:MOTS) to $3.75 from $6, reflecting a lower sales multiple and reduced estimates after the company’s third quarter report. The stock closed...